report_lead_image_with_gradient.png
2025

Emerging Space Brief: Bioprinting

Download this Report
To download this report, please complete the form below

Bioprinting investment booms: Nearly $335 million raised as market moves toward commercialization

Bioprinting is rapidly moving from science fiction to scientific reality. This emerging field—at the intersection of regenerative medicine, advanced materials, and precision manufacturing—is drawing surging interest from investors, with nearly $335 million raised in the past year alone. Our latest emerging space brief explores how startups are bioprinting tissues for drug testing, skin grafts, and even functional organ prototypes, while major players like Novo Nordisk and United Therapeutics double down on billion-dollar partnerships. From bone implants already in surgery to 3D-printed livers in the lab, bioprinting is no longer just about the future—it is reshaping what is possible in healthcare right now.